Acute Leukemia Classification and Diagnosis

Acute leukemia is diagnosed when immature hematopoietic cells (blasts) accumulate in the bone marrow and blood as a result of arrested maturation. Establishing the diagnosis and assigning a subtype rests on integrating morphology, cytochemistry, immunophenotype, cytogenetics, and molecular genetics, and on first separating the two main lineages: acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Definition

Acute leukemia is a clonal hematopoietic neoplasm defined by the accumulation of immature blast cells owing to a block in differentiation, diagnosed and subclassified by integrating morphology, immunophenotype, cytogenetics, and molecular genetics, and assigned to a myeloid (AML) or lymphoid (ALL) lineage.

Scope

This topic covers how acute leukemias are recognized and categorized: the diagnostic blast threshold, the distinction between myeloid and lymphoid acute leukemia, the role of recurrent genetic abnormalities, and the consensus classification systems that structure the field. It is reference material on diagnostic reasoning and classification, not a protocol for managing patients.

Key concepts

• Blast cell and the diagnostic blast percentage
• Myeloid versus lymphoid lineage assignment
• Recurrent genetic abnormalities defining entities
• Genetics-defined versus differentiation-defined subtypes
• Acute promyelocytic leukemia as a distinct entity
• Mixed-phenotype acute leukemia
• Integration of morphology, immunophenotype, and genetics

Mechanisms

Acute leukemia results from somatic genetic lesions in a hematopoietic progenitor that both drive proliferation and arrest maturation, so immature blasts accumulate. Diagnosis traditionally required a defined proportion of blasts in marrow or blood, but modern systems make the diagnosis genetics-first for several entities: certain recurrent abnormalities (for example specific fusion genes) are leukemia-defining regardless of the exact blast count. Lineage is assigned by immunophenotype, and entities are then refined by cytogenetic and molecular findings (Arber et al., 2016; Arber et al., 2022; Khoury et al., 2022).

Clinical relevance

Accurate classification of acute leukemia underlies prognostic stratification and the comparison of outcomes across studies, and reading a leukemia report requires understanding the diagnostic categories. This entry describes the classification framework at a reference level and is not guidance for diagnosing or treating an individual patient.

Epidemiology

AML is predominantly a disease of older adults with rising incidence in later life, whereas ALL has a marked peak in early childhood and is the most common pediatric cancer; both also occur across other age groups with differing biology (Dohner et al., 2015; Hunger & Mullighan, 2015).

Evidence & guidelines

Diagnosis and subtyping follow consensus classification systems: the WHO 2016 revision, the WHO 5th edition (2022), and the 2022 International Consensus Classification, which differ in some thresholds and category definitions but share the principle of integrating morphology, immunophenotype, cytogenetics, and molecular data (Arber et al., 2016; Khoury et al., 2022; Arber et al., 2022).

History

Acute leukemia classification evolved from the morphology-based French-American-British scheme to the genetics-integrating WHO systems, with successive revisions increasingly defining entities by recurrent molecular and cytogenetic abnormalities rather than morphology alone (Arber et al., 2016).

Debates

Should a fixed blast percentage still define acute myeloid leukemia?

The WHO 5th edition and the International Consensus Classification handle the blast threshold differently for genetically defined AML, reflecting an ongoing shift from morphology-based to genetics-based diagnosis and some divergence between the two systems.

Seminal works

• arber-2016
• arber-2022-icc
• khoury-2022

Frequently asked questions

What separates acute myeloid from acute lymphoblastic leukemia?

The lineage of the blast cells, determined chiefly by immunophenotype and supported by morphology, cytochemistry, and genetics; AML arises from myeloid precursors and ALL from lymphoid precursors.

Is a specific blast count always required to diagnose acute leukemia?

Not for every entity. Several acute leukemias are defined by recurrent genetic abnormalities that are themselves diagnostic, so for those the exact blast percentage is less decisive than in purely morphology-based schemes.